Home/Filings/4/0001567619-20-018003
4//SEC Filing

Nuechterlein Carole 4

Accession 0001567619-20-018003

CIK 0001799448other

Filed

Oct 19, 8:00 PM ET

Accepted

Oct 20, 4:55 PM ET

Size

15.7 KB

Accession

0001567619-20-018003

Insider Transaction Report

Form 4
Period: 2020-10-20
Transactions
  • Conversion

    Common Stock

    2020-10-20+283,5503,092,340 total(indirect: See footnote)
  • Conversion

    Series B-2 Preferred Stock

    2020-10-20283,5500 total(indirect: See footnote)
    Common Stock (283,550 underlying)
  • Conversion

    Series B-1 Preferred Stock

    2020-10-20662,7990 total(indirect: See footnote)
    Common Stock (662,799 underlying)
  • Conversion

    Common Stock

    2020-10-20+2,145,9912,145,991 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-10-20+662,7992,808,790 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-10-202,145,9910 total(indirect: See footnote)
    Common Stock (2,145,991 underlying)
Footnotes (2)
  • [F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
  • [F2]Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.

Documents

1 file

Issuer

Aligos Therapeutics, Inc.

CIK 0001799448

Entity typeother

Related Parties

1
  • filerCIK 0001665133

Filing Metadata

Form type
4
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 4:55 PM ET
Size
15.7 KB